quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 3, 2025

Toymaker Gears Up for Supreme Court Fight Over Trump’s Tariffs

View original at finance.yahoo.com
Toymaker Gears Up for Supreme Court Fight Over Trump’s Tariffs (Bloomberg) — Ask Rick Woldenberg why he’s challenging President Donald Trump’s tariffs at the US Supreme Court, and he might mention a furry unicorn yoga ball…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The tariffs have already helped secure multiple trade deals that level the playing field for American workers and industries and are securing trillions in investments to make and hire in America

    80% confidence
  • The administration has backup plans and the president's trade team is working diligently on contingency plans if tariffs are struck down

    80% confidence
  • Manufacturing overseas reflects longstanding industry practice due to lower labor costs abroad, not because companies don't invest in America

    80% confidence
  • The companies are like itinerant refugees in how they make products, going from jurisdiction to jurisdiction, and no matter what they guess, it seems wrong

    80% confidence
  • He doesn't think he will attend oral arguments, reversing himself after suggesting he might watch proceedings in person, to avoid deflecting from the importance of the decision

    80% confidence
  • To the president, these cases present a stark choice: With tariffs, we are a rich nation; without tariffs, we are a poor nation

    80% confidence
  • When taken all together, Trump's tariffs clearly are a net benefit for the country and for American workers

    80% confidence
  • Tariffs will raise revenue, open up foreign markets, and bring manufacturing jobs back to the US

    80% confidence
  • We paid a $50,000 penalty for the BubblePlush shipment arriving six hours late before the 50% India tariff took effect

    80% confidence
  • The president has no power to impose taxes on American citizens without the authorization of Congress, and tariffs are taxes on American importers

    80% confidence
  • He expects to incur millions of dollars in legal bills even after accepting contributions from unnamed outsiders

    80% confidence
  • He won't take help from non-Americans or anyone with political affiliations and is not a front for anyone else

    80% confidence
  • THE MOST IMPORTANT CASE EVER IS IN THE UNITED STATES SUPREME COURT

    80% confidence
  • He was shocked that those with much more power and money did not step up to challenge the tariffs

    80% confidence
  • He doesn't personally tell himself he's taking on Donald Trump, but advocating for himself, people who depend on the company, and issues important to every American

    80% confidence
  • Expected tariff bill for 2025 is $20-30 million, far above last year's $2.3 million

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Toymaker Gears Up for Supreme Court Fight Over Trump’s Tariffs — Source | Via News | pt.VIA.NEWS